Go Deep
UroGen Pharma Ltd.
UroGen Pharma Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -27,924 | -19.4 | -14.13 | -1.22 | 3,643.64 |
| Oct 2026 | -27,448 | -18.6 | -13.51 | -1.22 | 3,473.18 |
| Oct 2026 | -27,457 | -19.5 | -13.52 | -1.22 | 3,476.52 |
| Oct 2026 | -26,875 | -17.5 | -12.76 | -1.22 | 3,273.35 |
| Oct 2026 | -26,759 | -17.3 | -12.61 | -1.22 | 3,237.98 |
| Oct 2026 | -27,003 | -17.8 | -12.93 | -1.22 | 3,319.52 |
| Oct 2026 | -27,136 | -18.0 | -13.10 | -1.22 | 3,355.78 |
| Oct 2026 | -27,042 | -17.8 | -12.98 | -1.22 | 3,317.84 |
UroGen Pharma Ltd. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 72,456,000.0 | 50,959,000.0 | 37,837,000.0 | 27,482,000.0 |
| Net Profit | -14,351,000.0 | -23,574,000.0 | -26,364,000.0 | -33,347,000.0 |
| EPS | -0.3 | -0.5 | -0.5 | -0.7 |
UroGen Pharma Ltd. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 109,788,000.0 | 90,398,000.0 | 82,713,000.0 | 64,357,000.0 | — |
| Net Profit | -153,494,000.0 | -126,874,000.0 | -102,244,000.0 | -109,783,000.0 | — |
| EPS | -3.2 | -3.0 | -3.5 | -4.8 | — |
UroGen Pharma Ltd. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 200,455,000.0 | 285,711,000.0 | 178,311,000.0 | 135,619,000.0 | — |
| Total Liabilities | 305,929,000.0 | 294,514,000.0 | 243,523,000.0 | 224,980,000.0 | — |
| Total Equity | -105,474,000.0 | -8,803,000.0 | -65,212,000.0 | -89,361,000.0 | — |
Owes vs Owns
UroGen Pharma Ltd. owed $1.52 for every $1 it owned in Jun 2026, down from $1.66 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.52× | 1.53× | 1.03× | 1.37× | 1.66× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
UroGen Pharma Ltd. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 60.1%Receivables 16.5%Inventory 8.2%Fixed assets (tangible) 4.5%Other assets 10.7%
How it's funded — Dec 2025
Long-term debt 39.9%Payables 4.0%Other liabilities 56.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 120.5 | 236.7 | 137.0 | 100.0 |
| Receivables | 33.1 | 20.3 | 15.4 | 12.7 |
| Inventory | 16.5 | 9.2 | 5.7 | 4.3 |
| Fixed assets (tangible) | 9.1 | 3.8 | 2.4 | 3.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 5.0 | 4.5 | 0.0 |
| Other assets | 21.4 | 10.7 | 13.4 | 14.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 122.2 | 121.7 | 98.6 | 97.5 |
| Payables | 12.1 | 10.9 | 6.5 | 5.5 |
| Other liabilities | 171.6 | 161.8 | 138.5 | 121.9 |
| Shareholders' equity | -105.5 | -8.8 | -65.2 | -89.4 |
| Net tangible assets | -105.5 | -8.8 | -65.2 | -89.4 |
UroGen Pharma Ltd. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -162,444,000.0 | -96,766,000.0 | -76,376,000.0 | -87,559,000.0 | — |
| Investing Activities | 61,558,000.0 | -20,613,000.0 | -953,000.0 | 1,060,000.0 | — |
| Financing Activities | 39,918,000.0 | 194,619,000.0 | 116,931,000.0 | 97,134,000.0 | — |